Related Experiment Video
Updated: Mar 7, 2026

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
Published on: October 17, 2025
Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia
Hagop Kantarjian1, Anthony Stein1, Nicola Gökbuget1
1From the Department of Leukemia, University of Texas M.D. Anderson Cancer Center, Houston (H.K.); City of Hope National Medical Center, Duarte (A.S.), and Amgen, Thousand Oaks (A.F., D.N., Z.Z.) - both in California; Goethe University, University Hospital, Department of Medicine II, Frankfurt am Main (N.G.), Medical Department II (H.-A.H., M.B.) and Hematopathology Section and Lymph Node Registry (W.K.), University Hospital Schleswig Holstein, Campus Kiel, Kiel, and Medizinische Klinik und Poliklinik II, Universitätsklinikums Würzburg, Würzburg (M.S.T.) - all in Germany; Royal Free Hospital and University College London Cancer Institute, London (A.K.F.); Princess Margaret Cancer Centre, Toronto (A.C.S.), and Centre Intégré Universitaire de Santé et de Services Sociaux de l'est de l'île de Montréal, Hôpital Maisonneuve-Rosemont, Montreal (J.B.) - all in Canada; ICO-Hospital Universitari Germans Trias i Pujol, Jose Carreras Research Institute, Universitat Autonoma de Barcelona, Barcelona (J.-M.R.), the Department of Medicine, Hospital Universitari i Politecnic La Fe, University of Valencia, Valencia, and Centro de Investigación Biomédica en Red de Cáncer, Instituto Carlos III, Madrid (M.A.S.) - all in Spain; Alfred Hospital and Monash University, Melbourne, VIC, Australia (A.W.); Institut Universitaire d'Hématologie, Hôpital Saint-Louis (Assistance Publique - Hôpitaux de Paris), Paris (H.D.), and Centre Hospitalier Lyon Sud, Pierre-Benite (X.T.) - both in France; Ematologia, Dipartimento di Biotecnologie Cellulari ed Ematologia, Azienda Ospedaliera Policlinico Umberto I, Università Sapienza di Roma, Rome (R.F.), Azienda Unità Locale Socio Sanitaria 12 Veneziana Ospedale Dell Angelo, Venice (R.B.), and Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII, Bergamo, Università Statale di Milano, Milan (A.R.) - all in Italy; Ankara Universitesi, Tip Fakültesi, Cebeci Arastirma ve Uygulama Hastanesi, Ankara (Ö.A.), and Dokuz Eylül Üniversitesi Tıp Fakültesi, İzmir (F.D.) - both in Turkey; Instytut Hematologii i Transfuzjologii and Centrum Medyczne Kształcenia Podyplomowego, Warsaw, Poland (E.L.-M.); University of Washington Medical Center, Seattle (B.L.W.); and Amgen, Washington, DC (C.H.).
Blinatumomab significantly improves overall survival in adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). This bispecific antibody therapy offers a more effective treatment option compared to standard chemotherapy for ALL patients.
Area of Science:
- Hematology
- Immunology
- Oncology
Background:
- Blinatumomab is a bispecific monoclonal antibody targeting CD19+ ALL blasts by engaging CD3+ T cells.
- Previous single-group trials demonstrated blinatumomab's efficacy and manageable toxicity in relapsed/refractory B-cell precursor ALL.
- This study aimed to compare blinatumomab with standard chemotherapy in a larger patient cohort.
Purpose of the Study:
- To evaluate the efficacy of blinatumomab compared to standard chemotherapy in adult patients with relapsed or refractory B-cell precursor ALL.
- To determine the impact of blinatumomab on overall survival, remission rates, and event-free survival.
Main Methods:
- A multi-institutional phase 3 trial randomized 405 adults with heavily pretreated B-cell precursor ALL to receive blinatumomab or standard chemotherapy in a 2:1 ratio.
- The primary endpoint was overall survival.
- Patients received at least one dose of their assigned treatment.
Main Results:
- Blinatumomab significantly improved median overall survival (7.7 months vs. 4.0 months; P=0.01).
- Higher remission rates were observed with blinatumomab (complete remission: 34% vs. 16%; P<0.001).
- Blinatumomab also led to superior event-free survival (6-month estimates: 31% vs. 12%; P<0.001) and longer remission duration.
Conclusions:
- Blinatumomab offers a significant survival benefit over standard chemotherapy for adult patients with relapsed or refractory B-cell precursor ALL.
- The study confirms blinatumomab as a superior treatment option, demonstrating improved survival and remission rates.
- Allogeneic stem-cell transplantation rates were similar between groups, and high-grade adverse events were comparable.
More Related Videos
06:08Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
Published on: February 10, 2023
10:49Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
Published on: September 18, 2013
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...